TY - JOUR
T1 - Generic and brand-name thyroid hormone drug use among commercially insured and Medicare beneficiaries, 2007 through 2016
AU - Ross, Joseph S.
AU - Rohde, Stefanie
AU - Sangaralingham, Lindsey
AU - Brito, Juan P.
AU - Choi, Lauren
AU - Dutcher, Sarah K.
AU - Graham, David J.
AU - Jenkins, Marjorie R.
AU - Lipska, Kasia J.
AU - Mendoza, Martin
AU - Qiang, Yandong
AU - Wang, Zhong
AU - Wu, Yute
AU - Yao, Xiaoxi
AU - Shah, Nilay D.
N1 - Funding Information:
This work was supported by a Center of Excellence in Regulatory Science and Innovation (CERSI) grant to Yale University and Mayo Clinic from the US Food and Drug Administration (Grant U01FD005938 to J.S.R.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services or the US Food and Drug Administration.
Funding Information:
Disclosure Summary: L.C., S.K.D., D.J.G., M.R.J., M.M., Z.W., Y.W. are employed by the US Food and Drug Administration. J.S.R. has received research support through Yale University from Johnson and Johnson; Medtronic, Inc.; the US Food and Drug Administration (FDA) Grant U01FD004585; Blue CrossBlueShieldAssociation;CentersofMedicareandMedicaid Services (CMS) Grant HHSM-500-2013-13018I; Agency for Healthcare Research and Quality Grant R01HS022882; National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) Grant R01HS025164; and Laura and John Arnold Foundation. N.D.S. has received research support through Mayo Clinic from the Centers of Medicare and Medicaid Innovation; Agency for Healthcare Research and Quality Grants R01HS025164, R01HS025402, R03HS025517, and U19HS024075; NHLBI/NIH Grants R56HL130496 and R01HL131535; National Science Foundation; and Patient Centered Outcomes Research Institute (PCORI). K.J.L. receives support from the Centers of Medicare and Medicaid Services (CMS); National Institute on Aging and the American Federation of Aging Research through Paul Beeson Career Development Award K23AG048359; and Yale’s Claude D. Pepper Older Americans Independence Center Grant P30AG021342. J.P.B. is supported by the Karl-Erivan Haub Family Career De-velopmentAwardinCancerResearchatMayoClinicinRochester. S.R. received a student research grant provided by the Yale School of Medicine Office of Student Research under NIH training grant T35DK104689. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Theremainingauthorshavenothingtodisclose.Theauthors assume full responsibility for the accuracy and completeness of the ideas presented.
Funding Information:
Financial Support: This work was supported by a Center of Excellence in Regulatory Science and Innovation (CERSI) grant to Yale University and Mayo Clinic from the US Food and Drug Administration (Grant U01FD005938 to J.S.R.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services or the US Food and Drug Administration.
Publisher Copyright:
Copyright © 2019 Endocrine Society
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Context: Generic drugs account for 9 out of 10 prescriptions dispensed in the United States but for a lower proportion of commonly prescribed thyroid hormone replacement therapies. Objective: Characterize temporal patterns of generic and brand-name thyroid hormone drug use, including patient and prescriber characteristics associated with brand-name use. Design and Setting: Cross-sectional longitudinal analysis of national data from a large administrative claims database from January 2007 through December 2016. Patients: Adults with insurance coverage through commercial, Medicare Advantage, and Medicare Part D health plans. Main Outcome Measures: Generic and brand-name thyroid hormone drug use. Results: From 2007 to 2016, the annual number of thyroid hormone treatment pharmacy fills increased from 8,905,836 in 2007 to 11,613,923 in 2016, 73.6% of which were for generic levothyroxine, 23.4% for brand-name levothyroxine, and the remaining for other formulations. Dispensing of generic thyroid hormone drugs increased from 59.8% in 2007 to 84.9% in 2016 and was consistently higher among Medicare Advantage and Medicare Part D when compared with the commercial beneficiary population. For all three beneficiary populations, use of brand-name products was less common among older adults and more common among women and those receiving prescriptions from endocrinologists and was more common among those of white race and with greater household income for the Medicare Advantage and commercial beneficiary populations (P, 0.001). Conclusions: Brand-name thyroid hormone product use declined from 2007 to 2016 among three large, national insurer beneficiary populations. Although certain patient characteristics were associated with brand-name use, prescriber specialty was the strongest predictor.
AB - Context: Generic drugs account for 9 out of 10 prescriptions dispensed in the United States but for a lower proportion of commonly prescribed thyroid hormone replacement therapies. Objective: Characterize temporal patterns of generic and brand-name thyroid hormone drug use, including patient and prescriber characteristics associated with brand-name use. Design and Setting: Cross-sectional longitudinal analysis of national data from a large administrative claims database from January 2007 through December 2016. Patients: Adults with insurance coverage through commercial, Medicare Advantage, and Medicare Part D health plans. Main Outcome Measures: Generic and brand-name thyroid hormone drug use. Results: From 2007 to 2016, the annual number of thyroid hormone treatment pharmacy fills increased from 8,905,836 in 2007 to 11,613,923 in 2016, 73.6% of which were for generic levothyroxine, 23.4% for brand-name levothyroxine, and the remaining for other formulations. Dispensing of generic thyroid hormone drugs increased from 59.8% in 2007 to 84.9% in 2016 and was consistently higher among Medicare Advantage and Medicare Part D when compared with the commercial beneficiary population. For all three beneficiary populations, use of brand-name products was less common among older adults and more common among women and those receiving prescriptions from endocrinologists and was more common among those of white race and with greater household income for the Medicare Advantage and commercial beneficiary populations (P, 0.001). Conclusions: Brand-name thyroid hormone product use declined from 2007 to 2016 among three large, national insurer beneficiary populations. Although certain patient characteristics were associated with brand-name use, prescriber specialty was the strongest predictor.
UR - http://www.scopus.com/inward/record.url?scp=85065556950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065556950&partnerID=8YFLogxK
U2 - 10.1210/jc.2018-02197
DO - 10.1210/jc.2018-02197
M3 - Article
C2 - 30690529
AN - SCOPUS:85065556950
VL - 104
SP - 2305
EP - 2314
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 6
ER -